Trial Profile
Combination of Low Dose Antiestrogens With Omega-3 Fatty Acids for Prevention of Hormone-independent Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Omega-3-acid ethyl esters (Primary) ; Raloxifene (Primary)
- Indications Breast cancer
- Focus Biomarker; Pharmacodynamics
- 30 Jan 2013 Planned end date changed from 1 Oct 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 30 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Aug 2012 Interim results from feasibility and biomarker analysis published in the European Journal of Clinical Nutrition.